NCT00032175已完成3 期
A Phase III Multicenter Randomized Clinical Trial Comparing Gemcitabine Alone Or In Combination With Capecitabine For The Treatment Of Patients With Advanced Pancreatic Cancer
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 508
- 试验地点
- 60
- 主要终点
- Survival at 1 year
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if gemcitabine is more effective with or without capecitabine in treating pancreatic cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine with or without capecitabine in treating patients who have locally advanced or metastatic pancreatic cancer.
详细描述
OBJECTIVES:
- Compare the 1-year survival rate of patients with locally advanced or metastatic pancreatic cancer treated with gemcitabine with or without capecitabine.
- Compare the median and 2-year survival rates and the objective response rates of patients treated with these regimens.
- Compare the toxicity of these regimens in these patients.
- Compare the quality of life of patients treated with these regimens.
OUTLINE: This is an randomized, open-label, multicenter study. Patients are stratified according to disease stage (locally advanced vs metastatic) and performance status (0 and 1 vs 2). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 1-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43 during the first course. After a 1-week rest period, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15. Subsequent courses repeat every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, every 3 months for 1 year, and then annually thereafter.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed ductal adenocarcinoma of the pancreas
- •Locally advanced or metastatic disease not amenable to curative surgical resection
- •Macroscopic residual disease after prior resection with histological confirmation is allowed
- •Unidimensionally measurable disease
- •No intracerebral metastases or meningeal carcinomatosis
- •PATIENT CHARACTERISTICS:
- •Performance status:
- •Life expectancy:
- •More than 3 months
- •Hematopoietic:
- •WBC greater than 3,000/mm3
- •Neutrophil count greater than 1,500/mm3
- •Platelet count greater than 100,000/mm3
- •Bilirubin less than 2 mg/dL
- •Creatinine less than 2 mg/dL
- •Creatinine clearance greater than 50 mL/min
- •Cardiovascular:
- •No New York Heart Association class III or IV heart disease
- •No uncontrolled angina pectoris
- •No other prior malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix
- •No other concurrent uncontrolled medical condition
- •No other medical or psychiatric condition that would preclude study
- •No known hypersensitivity to fluorouracil
- •No dihydropyrimidine dehydrogenase deficiency
- •No known malabsorption syndromes
- •Not pregnant or nursing
- •Fertile patients must use effective contraception
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •Not specified
- •Chemotherapy:
- •No prior chemotherapy (including preoperative or adjuvant) for this disease
- •No other concurrent cytotoxic chemotherapy
- •Endocrine therapy:
- •Not specified
- •Radiotherapy:
- •No prior radiotherapy (including preoperative or adjuvant) for this disease
- •See Disease Characteristics
- •No prior investigational drugs (including preoperative or adjuvant) for this disease
- •No other concurrent investigational drugs
- •No concurrent dipyridamole or allopurinol
- •No concurrent sorivudine or sorivudine analogs (e.g., brivudine) (capecitabine arm only)
排除标准
- 未提供
结局指标
主要结局
Survival at 1 year
次要结局
- Survival rate at 2 years
- Quality of life
- Median survival rate
- Toxicity
- Objective response rate
研究者
研究点 (60)
Loading locations...
相似试验
已完成
3 期
Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast CancerBreast CancerNCT00047255Jonsson Comprehensive Cancer Center263
已完成
3 期
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast CancerBreast CancerNCT00054587UNICANCER3,010
终止
3 期
Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast CancerBreast CancerNCT00053911UNICANCER
已完成
3 期
Vaccine Therapy in Treating Women With Metastatic Breast CancerBreast CancerNCT00003638Oncothyreon Canada Inc.950
已完成
3 期
High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast CancerBreast CancerNCT00002870UNICANCER180